Elixir Associates’ Post

Big news in oncology today! 🎉 Scorpion Therapeutics has just closed a $150 million Series C financing! 💰 This round was co-led by Frazier Life Sciences and Lightspeed Venture Partners, with significant contributions from existing and new investors. The funding will propel the mid-stage development of STX-478, a potentially groundbreaking treatment for breast cancer and other solid tumors. STX-478 shows great promise as a mutant-selective PI3Kα inhibitor. This could revolutionise treatment options for patients with PI3Kα mutations, a common driver of cancer. Scorpion's pipeline is robust, driven by an integrated small molecule discovery engine that's second to none. This financing will also support advancing their EGFR inhibitor franchise and next-gen precision oncology therapies. #Oncology #PrecisionMedicine #LifeSciences #CancerResearch #Investment